GLG LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 45 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
GLG LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2017$3,120,000
-43.1%
4,000,000
-28.6%
0.20%
-40.1%
Q2 2017$5,483,000
-35.4%
5,600,000
-38.5%
0.34%
-28.1%
Q1 2017$8,486,000
+16.7%
9,100,000
+12.3%
0.47%
-6.6%
Q4 2016$7,269,000
+6.3%
8,100,000
+32.8%
0.50%
+2.9%
Q3 2016$6,840,0006,100,0000.49%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2016
NameSharesValueWeighting ↓
Worth Venture Partners, LLC 5,324,000$4,995,0003.78%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$53,020,0002.12%
DLD Asset Management, LP 32,500,000$30,048,0002.06%
Castle Creek Arbitrage, LLC 4,504,000$4,161,0001.43%
TENOR CAPITAL MANAGEMENT Co., L.P. 10,000,000$9,372,0000.62%
Graham Capital Management, L.P. 14,636,000$13,509,0000.60%
OAKTREE CAPITAL MANAGEMENT LP 64,452,000$59,704,0000.54%
Context Capital Management, LLC 1,000,000$926,0000.52%
ADVENT CAPITAL MANAGEMENT /DE/ 23,118,000$21,341,0000.52%
WOLVERINE ASSET MANAGEMENT LLC 18,583,000$17,322,0000.21%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders